Reents Scott T 4
4 · AbbVie Inc. · Filed Feb 18, 2025
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
Transactions
- Award
Option (Right to buy)
2025-02-13+27,343→ 27,343 totalExercise: $192.86Exp: 2035-02-12→ Common Stock (27,343 underlying) - Award
Common Stock, $0.01 par value
2025-02-13+8,912→ 32,586 total - Award
Common Stock, $0.01 par value
2025-02-13+5,845→ 21,276 total - Award
Common Stock, $0.01 par value
2025-02-13+2,398→ 23,674 total - Award
Common Stock, $0.01 par value
2025-02-13+7,608→ 40,194 total
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,115 on February 13, 2026, 9,114 on February 13, 2027, and 9,114 on February 13, 2028.